Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19.
The information gained from the study can be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines, other prevention strategies, and treatments.
Full description
This is a prospective study of acute immune responses to SARSCoV-2 infection.
The study will include 3 groups, as described in the table below. Groups are defined based on clinical status at enrollment, but for the purposes of data analysis, participants who experience disease progression can contribute data to other cohorts.
Participants will complete six visits over 28 days followed by a health contact at Month 2 (one month after the last scheduled visit). Additional follow up visit(s) may be added over time in response to evolving information regarding SARS-CoV-2 infection and COVID-19.
Study visits may include review of medical history; interviews/questionnaires; pregnancy tests (for participants assigned female sex at birth); blood draws; nasal swab, nasal wash, and saliva sample collection; and optional stool sample collection.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 18 years or older.
Test result indicating presence of SARS-CoV-2 virus. Sites must have results from assays that are approved as FDA-emergency use authorized or as standard-of-care by other applicable regional governing bodies. For timing of testing, please see group specific criteria below.
Ability and willingness to provide informed consent.
Willingness to have clinical research staff come to place of residence or hospital if needed.
Willingness to be followed for the planned duration of the study.
Assessment of understanding: volunteer demonstrates understanding of this study.
Agreement to allow access to medical records.
Asymptomatic participants:
Symptomatic (non-hospitalized) participants:
Symptomatic (hospitalized) participants
Exclusion criteria
953 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal